Profile
AKAN ZTS TAK HLN TEVA NBIX
Company Name Akanda Corp. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $3.12M $82.06B $43.45B $42.15B $19.37B $14.77B
Employees 0.05K 14.10K 49.28K 25.41K 35.00K 1.45K
CEO Ms. Katharyn Field Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Dr. Kevin C. Gorman Ph.D.
Ratings
AKAN ZTS TAK HLN TEVA NBIX
Quant Rating Score 2 3 2 3 1 3
Quant Rating Sell Neutral Sell Neutral Strong Sell Neutral
Trading
AKAN ZTS TAK HLN TEVA NBIX
Last Close $1.63 $179.84 $13.77 $9.23 $17.1 $146.8
High 52 $4.11 $200.09 $16.32 $9.23 $17.4 $147.46
Low 52 $0.09 $145.54 $12.6 $7.78 $8.12 $101.19
Price vs. 52 Week High -60.34 % -10.12 % -15.63 % 0 % -1.72 % -0.45 %
Price vs. 52 Week Low 1711.11 % 23.57 % 9.29 % 18.64 % 110.59 % 45.07 %
Total Return
AKAN ZTS TAK HLN TEVA NBIX
1 Month Return -32.08 % 1.92 % 6.66 % 9.49 % 5.17 % 9.3 %
3 Month Return 1482.52 % 13.52 % 5.68 % 9.23 % 23.82 % 7.95 %
6 Month Return 297.66 % -6.1 % -5.68 % 12.97 % 43.58 % 3.27 %
9 Month Return 248.96 % 15.26 % 2.27 % 18.49 % 110.59 % 38.4 %
YTD Return 270.03 % -8.88 % -3.5 % 12.15 % 63.79 % 11.41 %
1 Year Return 159.14 % -4.69 % -11.79 % 6.28 % 103.09 % 44.99 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AKAN ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 0.93 % 4.08 % 2.12 % - -
Dividend Paid and Capex Coverage Ration (TTM) -999.05 % 1.76 % 0.92 % - 3.3 % 20.82 %
Dividend Per Share (TTM) - 1.67 % 0.56 % 0.15 % - -
Payout Ratio (TTM) - 29.95 % 199.34 % - - -
Growth
AKAN ZTS TAK HLN TEVA NBIX
Asset Growth -77.33 % -4.28 % 8.25 % -2.18 % -1.2 % 37.27 %
Gross Profit Growth -426.32 % 3.7 % -16.6 % 5.85 % 9.64 % 26.06 %
Revenue Growth -17.55 % 5.74 % 5.87 % 4.09 % 6.16 % 26.76 %
Revenue 3 Year 67104.7 % 31.98 % 33.13 % 13.9 % -6.92 % 71.93 %
Revenue 5 Year - 53.64 % 149.89 % 32.87 % -23.33 % 308.36 %
Revenue 10 Year - 103.1 % 154.38 % 32.87 % -40.82 % 44100.16 %
EBIT Growth 50.88 % 6.27 % 7.34 % 37.26 % -84.52 % 0.76 %
Net Income Growth -8228.82 % 10.88 % -54.56 % -1.04 % 76.24 % 61.62 %
Net Income 3 Yeari Growth Per Share -602.85 % 47.55 % -61.74 % -8.67 % 86.29 % -41.58 %
Net Income 5 Yeari Growth Per Share -996.44 % 71.94 % 62.27 % 59.66 % 76.28 % 1054.95 %
Net Income 10 Yeari Growth Per Share -996.44 % 404.24 % 36.33 % 59.66 % -133.42 % 470.4 %
Operating Income Growth 50.88 % 6.27 % 7.34 % 37.26 % -84.52 % 0.76 %
Operating Cash Flow Growth (CFG) 86.92 % 23.06 % -34.47 % -16.48 % -13.96 % 14.88 %
Operating 3 Year CFG 28.82 % 14.12 % -36.76 % 22.08 % 10.09 % 62.6 %
Operating 5 Year CFG -49.87 % 37.69 % 139.61 % 118.54 % -48.98 % 275.6 %
Operating 10 Year CFG -49.87 % 274.61 % 335.67 % 118.54 % -67.94 % 1000.37 %
EPS Growth -6609.09 % 12.64 % -54.92 % - 76.42 % 59.01 %
EPS Diluted Growth -6609.09 % 12.92 % -54.86 % - 76.42 % 58.33 %
Book Value Per Share -110.94 % 15.34 % 13.54 % 1.38 % -5.72 % 28.15 %
Share Holder 3 Year Equity Growth Per Share 51.18 % 36.7 % 40.38 % -36.6 % -26.74 % 88.86 %
Share Holder 5 Year Equity Growth Per Share - 139.55 % 73.27 % -39.41 % -53.44 % 353.33 %
Share Holder 10 Year Equity Growth Per Share - 476.36 % 197.1 % -39.41 % -74.76 % 1167.34 %
Dividend Per Share Growth - 15.15 % 1.95 % -85.58 % - -
Dividend 3 Year Growth Per Share - 87.76 % 1.19 % -83.69 % - -
Dividend 5 Year Growth Per Share - 198.29 % - -66.42 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % 103.93 % -66.42 % -100 % -
Debt Growth 2.54 % -15.91 % 24.67 % -9.43 % -6.53 % 62.95 %
Free Cash Flow Growth 87.25 % 22.25 % -53.54 % -20.06 % -19.19 % 11.99 %
Updated On 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023 31 Dec 2023
Profitability
AKAN ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM -196.66 % 69.2 % 66.54 % 60.04 % 48.99 % 97.78 %
Return on Assets TTM -547.65 % 16.66 % 0.95 % - -1.15 % 10.65 %
Return on Equity TTM -543.35 % 48.41 % 2.06 % 6.53 % -6.86 % 17.45 %
Return on Capital Employed TTM 1121.62 % 25.86 % 3.22 % - 3.75 % 17.05 %
Net Income Per EBT TTM 100 % 80.07 % 293.72 % 64.62 % 59.18 % 78.68 %
EBT Per Ebit TTM 324.11 % 92.82 % 11.92 % 82.52 % -76.63 % 99.89 %
EBIT Per Revenue TTM -461.01 % 36.83 % 9.65 % 18.08 % 6.79 % 23.73 %
Cash Flow To Debt Ratio TTM -56.29 % 36.43 % 14.47 % - 8.57 % 118.01 %
Receivables Turnover TTM 11.39 6.75 6.11 - 4.63 4.4
Payables Turnover TTM 1.6 6.64 4.46 - 3.35 0.5
Inventory Turnover TTM 7.47 1.01 1.18 - 2.07 1.18
Fixed Asset Turnover TTM 122.67 % 251.27 % 214.28 % - 267.75 % 572.67 %
Asset Turnover TTM 36.65 % 60.87 % 28.22 % - 37.45 % 57.08 %
Operating Cash Flow Per Share TTM -0.49 5.24 452.66 - 1.5 6.47
Free Cash Flow Per Share TTM -0.49 3.82 146.27 - 1.04 6.16
Cash Per Share TTM 2.03 % 431.22 % 29177.57 % 22.71 % 266.34 % 1213.03 %
Operating Cash Flow Sales Ratio TTM -69.47 % 27.47 % 16.66 % - 10.51 % 32.56 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.1 % 72.95 % 32.31 % - 69.66 % 95.2 %
Cash Flow Coverage Ratios TTM -56.29 % 36.43 % 14.47 % - 8.57 % 118.01 %
Price To Free Cash Flows Ratio TTM -1.39 46.89 29.1 - 16.51 24.05
Price To Operating Cash Flows Ratio TTM -3.35 34.33 4.68 - 11.4 22.7
Price Cash Flow Ratio TTM -3.35 34.33 4.68 - 11.4 22.7
Income Statement (TTM)
AKAN ZTS TAK HLN TEVA NBIX
Revenue $0B $8.54B $4263.76B $11.3B $15.85B $1.89B
Gross Profit $-0.01B $5.83B $2321.31B $6.96B $7.65B $1.85B
Gross Profit Ratio -297.58% 68.28% 54.44% 61.6% 48.25% 97.9%
EBITDA $-0.01B $3.56B $1254.52B $2.81B $4.27B $0.42B
Net Income $-0.03B $2.34B $144.07B $1.05B $-0.56B $0.25B
EPS Diluted -7.16 5.07 91.16 0.11 -0.5 2.47
Balance Sheet (MRQ)
AKAN ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $6.56B $4476.5B $8.8B $18.48B $0.26B
Total Liabilities $0.01B $9.3B $7834.79B $17.33B $35.35B $1.02B
Total Equity $-0B $4.99B $7274.01B $16.73B $8.13B $2.23B
Total Investments $0B $0.02B $683.22B $0.07B $0.01B $0.94B
Total Debt $0B $6.8B $5463.39B $9.46B $20.15B $0.43B
Total Assets $0.01B $14.29B $15108.79B $34.06B $43.48B $3.25B
Cash Flow Statement (TTM)
AKAN ZTS TAK HLN TEVA NBIX
Net Income $-0.03B $2.34B $144.07B $1.05B $-0.62B $0.25B
Inventory $0B $-0.36B $-115.74B $-0.13B $-0.15B $0.01B
Dividends Paid $0B $-0.69B $-287.19B $-0.39B $0B $0B
Operating Cash Flow $-0B $2.35B $640.32B $1.72B $1.37B $0.39B
Capital Expenditure $-0B $-0.73B $-480.73B $-0.34B $-0.53B $-0.03B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 5.9
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.45
ALIM Alimera Sciences, Inc. 5.57
ALVO Alvotech 11.59
ALVOW Alvotech 2.59
AMPH Amphastar Pharmaceuticals, Inc. 42.48
AMRX Amneal Pharmaceuticals, Inc. 7.44
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 63.25
AQST Aquestive Therapeutics, Inc. 3.82
ASRT Assertio Holdings, Inc. 1.505
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 16.72
AYTU Aytu BioPharma, Inc. 2.7
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to AKAN
Ticker ETF Name Weight Percentage Price
MJ ETFMG Alternative Harvest ETF 0 3.58
Unlock